Closely watched Parkinson's drug from Biogen, Denali comes up short
Biogen and Denali Therapeutics have announced that their experimental Parkinson's disease drug, BIIB122, has failed a key clinical trial. The mid-stage trial showed no significant improvement in slowing disease progression compared to a placebo. Denali plans to continue independent research on a subset of patients with a specific genetic variant linked to Parkinson's.
- ▪The drug was developed through a partnership formed in 2020 between Biogen and Denali Therapeutics.
- ▪The trial involved nearly 650 participants and aimed to assess the drug's effectiveness against a placebo.
- ▪Despite some exploratory analyses indicating engagement with the harmful enzyme, the overall results were disappointing.
Opening excerpt (first ~120 words) tap to expand
An article from Parkinson’s drug from Biogen, Denali comes up short High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients. Published May 22, 2026 Jacob Bell Lead Reporter Share Copy link Email LinkedIn X/Twitter Facebook Print License Add us on Google Biogen and Denali Therapeutics have been working on a Parkinson's disease drug under an alliance formed in 2020. Getty Images The outlook for an experimental Parkinson’s disease drug dimmed on Thursday with the announcement that it had failed a key clinical trial.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at BioPharma Dive.
Discussion
0 commentsMore from BioPharma Dive
